Annual SG&A
$1.34 B
-$73.86 M-5.21%
31 December 2023
Summary:
Jazz Pharmaceuticals annual selling, general & administrative expenses is currently $1.34 billion, with the most recent change of -$73.86 million (-5.21%) on 31 December 2023. During the last 3 years, it has risen by +$488.87 million (+57.23%). JAZZ annual SG&A is now -7.48% below its all-time high of $1.45 billion, reached on 31 December 2021.JAZZ Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$325.77 M
-$12.75 M-3.77%
30 September 2024
Summary:
Jazz Pharmaceuticals quarterly selling, general & administrative expenses is currently $325.77 million, with the most recent change of -$12.75 million (-3.77%) on 30 September 2024. Over the past year, it has increased by +$17.46 million (+5.66%). JAZZ quarterly SG&A is now -24.07% below its all-time high of $429.03 million, reached on 30 June 2021.JAZZ Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
$3.55 B
+$51.93 M+1.48%
30 September 2024
Summary:
Jazz Pharmaceuticals TTM selling, general & administrative expenses is currently $3.55 billion, with the most recent change of +$51.93 million (+1.48%) on 30 September 2024. Over the past year, it has increased by +$2.22 billion (+166.87%). JAZZ TTM SG&A is now -19.07% below its all-time high of $1.50 billion, reached on 31 March 2022.JAZZ TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
JAZZ Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.2% | +5.7% | +166.9% |
| 3 y3 years | +57.2% | -10.4% | +173.0% |
| 5 y5 years | +96.5% | +82.3% | +418.6% |
JAZZ Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -7.5% | +57.2% | -18.2% | +9.3% | -16.0% | +9.8% |
| 5 y | 5 years | -7.5% | +96.5% | -24.1% | +82.3% | -19.1% | +9.8% |
| alltime | all time | -7.5% | +5603.0% | -24.1% | +2285.4% | -19.1% | +273.5% |
Jazz Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $325.77 M(-3.8%) | $1.41 B(+1.3%) |
| June 2024 | - | $338.52 M(-3.7%) | $1.39 B(-0.2%) |
| Mar 2024 | - | $351.71 M(-11.2%) | $1.40 B(+4.0%) |
| Dec 2023 | $1.34 B(-5.2%) | $396.03 M(+28.5%) | $1.34 B(+1.0%) |
| Sept 2023 | - | $308.31 M(-9.5%) | $1.33 B(-3.6%) |
| June 2023 | - | $340.84 M(+14.4%) | $1.38 B(-1.8%) |
| Mar 2023 | - | $297.92 M(-22.3%) | $1.41 B(-0.8%) |
| Dec 2022 | $1.42 B(-2.4%) | $383.20 M(+6.9%) | $1.42 B(-1.1%) |
| Sept 2022 | - | $358.48 M(-2.2%) | $1.43 B(-0.4%) |
| June 2022 | - | $366.47 M(+18.7%) | $1.44 B(-4.2%) |
| Mar 2022 | - | $308.81 M(-22.5%) | $1.50 B(+3.3%) |
| Dec 2021 | $1.45 B(+69.9%) | $398.46 M(+9.6%) | $1.45 B(+11.6%) |
| Sept 2021 | - | $363.68 M(-15.2%) | $1.30 B(+13.7%) |
| June 2021 | - | $429.03 M(+64.7%) | $1.14 B(+26.2%) |
| Mar 2021 | - | $260.51 M(+5.4%) | $906.34 M(+6.1%) |
| Dec 2020 | $854.23 M(+15.9%) | $247.17 M(+19.3%) | $854.23 M(+4.0%) |
| Sept 2020 | - | $207.25 M(+8.3%) | $821.34 M(+3.6%) |
| June 2020 | - | $191.41 M(-8.2%) | $792.79 M(+2.0%) |
| Mar 2020 | - | $208.40 M(-2.7%) | $777.39 M(+5.5%) |
| Dec 2019 | $736.94 M(+7.8%) | $214.28 M(+19.9%) | $736.94 M(+7.7%) |
| Sept 2019 | - | $178.71 M(+1.5%) | $684.53 M(+3.5%) |
| June 2019 | - | $176.01 M(+4.8%) | $661.70 M(+2.7%) |
| Mar 2019 | - | $167.95 M(+3.8%) | $644.26 M(-5.7%) |
| Dec 2018 | $683.53 M(+25.6%) | $161.87 M(+3.8%) | $683.53 M(+2.8%) |
| Sept 2018 | - | $155.87 M(-1.7%) | $664.72 M(+4.9%) |
| June 2018 | - | $158.58 M(-23.5%) | $633.37 M(+4.3%) |
| Mar 2018 | - | $207.21 M(+44.9%) | $607.11 M(+11.6%) |
| Dec 2017 | $544.16 M(+8.2%) | $143.05 M(+14.9%) | $544.16 M(+3.0%) |
| Sept 2017 | - | $124.52 M(-5.9%) | $528.25 M(+0.0%) |
| June 2017 | - | $132.33 M(-8.3%) | $528.09 M(+1.9%) |
| Mar 2017 | - | $144.25 M(+13.5%) | $518.38 M(+3.1%) |
| Dec 2016 | $502.89 M(+12.0%) | $127.14 M(+2.2%) | $502.89 M(+0.3%) |
| Sept 2016 | - | $124.37 M(+1.4%) | $501.31 M(+4.2%) |
| June 2016 | - | $122.62 M(-4.8%) | $480.98 M(+3.3%) |
| Mar 2016 | - | $128.76 M(+2.6%) | $465.50 M(+3.6%) |
| Dec 2015 | $449.12 M | $125.56 M(+20.7%) | $449.12 M(+4.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2015 | - | $104.04 M(-2.9%) | $429.26 M(+2.5%) |
| June 2015 | - | $107.13 M(-4.7%) | $418.71 M(+1.6%) |
| Mar 2015 | - | $112.39 M(+6.3%) | $412.14 M(+1.5%) |
| Dec 2014 | $406.11 M(+33.5%) | $105.69 M(+13.0%) | $406.11 M(+6.4%) |
| Sept 2014 | - | $93.50 M(-7.0%) | $381.72 M(+5.1%) |
| June 2014 | - | $100.56 M(-5.5%) | $363.19 M(+6.8%) |
| Mar 2014 | - | $106.36 M(+30.8%) | $340.14 M(+11.8%) |
| Dec 2013 | $304.30 M(+35.9%) | $81.30 M(+8.4%) | $304.30 M(+7.0%) |
| Sept 2013 | - | $74.97 M(-3.3%) | $284.38 M(+5.2%) |
| June 2013 | - | $77.51 M(+9.9%) | $270.33 M(+8.1%) |
| Mar 2013 | - | $70.53 M(+14.9%) | $250.05 M(+11.7%) |
| Dec 2012 | $223.88 M(+105.5%) | $61.38 M(+0.7%) | $223.88 M(+12.6%) |
| Sept 2012 | - | $60.92 M(+6.5%) | $198.89 M(+18.0%) |
| June 2012 | - | $57.22 M(+29.0%) | $168.51 M(+26.3%) |
| Mar 2012 | - | $44.36 M(+21.9%) | $133.38 M(+22.4%) |
| Dec 2011 | $108.94 M(+57.9%) | $36.38 M(+19.1%) | $108.94 M(+21.6%) |
| Sept 2011 | - | $30.55 M(+38.3%) | $89.62 M(+16.2%) |
| June 2011 | - | $22.09 M(+11.0%) | $77.11 M(+6.9%) |
| Mar 2011 | - | $19.91 M(+16.6%) | $72.12 M(+4.5%) |
| Dec 2010 | $69.00 M(+17.6%) | $17.07 M(-5.4%) | $69.00 M(+2.0%) |
| Sept 2010 | - | $18.04 M(+5.5%) | $67.64 M(+4.6%) |
| June 2010 | - | $17.10 M(+1.8%) | $64.67 M(+5.6%) |
| Mar 2010 | - | $16.79 M(+6.8%) | $61.23 M(+4.4%) |
| Dec 2009 | $58.65 M(-47.4%) | $15.72 M(+4.4%) | $58.65 M(-7.1%) |
| Sept 2009 | - | $15.06 M(+10.3%) | $63.12 M(-12.8%) |
| June 2009 | - | $13.66 M(-3.9%) | $72.39 M(-22.0%) |
| Mar 2009 | - | $14.22 M(-29.6%) | $92.84 M(-16.7%) |
| Dec 2008 | $111.40 M(+41.8%) | $20.18 M(-17.0%) | $111.40 M(-6.5%) |
| Sept 2008 | - | $24.33 M(-28.7%) | $119.17 M(+5.5%) |
| June 2008 | - | $34.11 M(+4.1%) | $112.92 M(-1.3%) |
| Mar 2008 | - | $32.78 M(+17.3%) | $114.45 M(+19.2%) |
| Dec 2007 | $78.54 M(+52.8%) | $27.96 M(+54.7%) | $96.01 M(+41.1%) |
| Sept 2007 | - | $18.07 M(-49.3%) | $68.05 M(+36.2%) |
| June 2007 | - | $35.64 M(+148.6%) | $49.98 M(+248.6%) |
| Mar 2007 | - | $14.34 M | $14.34 M |
| Dec 2006 | $51.38 M(+118.2%) | - | - |
| Dec 2005 | $23.55 M | - | - |
FAQ
- What is Jazz Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals annual SG&A year-on-year change?
- What is Jazz Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals quarterly SG&A year-on-year change?
- What is Jazz Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals TTM SG&A year-on-year change?
What is Jazz Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of JAZZ is $1.34 B
What is the all time high annual SG&A for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high annual selling, general & administrative expenses is $1.45 B
What is Jazz Pharmaceuticals annual SG&A year-on-year change?
Over the past year, JAZZ annual selling, general & administrative expenses has changed by -$73.86 M (-5.21%)
What is Jazz Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of JAZZ is $325.77 M
What is the all time high quarterly SG&A for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $429.03 M
What is Jazz Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, JAZZ quarterly selling, general & administrative expenses has changed by +$17.46 M (+5.66%)
What is Jazz Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of JAZZ is $3.55 B
What is the all time high TTM SG&A for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high TTM selling, general & administrative expenses is $1.50 B
What is Jazz Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, JAZZ TTM selling, general & administrative expenses has changed by +$2.22 B (+166.87%)